AS
FULC icon

Altshuler Shaham’s Fulcrum Therapeutics FULC Stock Holding History

Altshuler Shaham’s Portfolio FULC Stock Details FULC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$767 Hold
100
– – ﹤0.01% 416
2025
Q4 		$1.13K Buy
+100
New +$1.02K ﹤0.01% 386

Other funds holding FULC

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
FTM
First Turn Management Del Mar, California $895M AUM 261.28% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Altshuler Shaham's FULC Position: Q1 2026 in Review

Altshuler Shaham held its Fulcrum Therapeutics (FULC) position steady in Q1 2026 at 100 shares worth $767. The position accounts for ﹤0.01% of the portfolio, ranked #416.

Altshuler Shaham first reported a position in FULC in Q4 2025 and has held it in 2 quarters since. The position peaked at $1.13K in Q4 2025. 169 funds tracked by Wall St. Rank hold FULC as of Q1 2026.

  • Altshuler Shaham held 100 shares of Fulcrum Therapeutics worth $767 as of Q1 2026.
  • Altshuler Shaham left its Fulcrum Therapeutics share count unchanged in Q1 2026.
  • Fulcrum Therapeutics made up ﹤0.01% of Altshuler Shaham's portfolio in Q1 2026, its #416 holding.
  • Altshuler Shaham first reported a position in Fulcrum Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Altshuler Shaham's Fulcrum Therapeutics position peaked at $1.13K in Q4 2025.
  • 169 funds tracked by Wall St. Rank held Fulcrum Therapeutics as of Q1 2026.

Based on Altshuler Shaham's 13F filing for Q1 2026, filed 18 May 2026.